ATLANTA, Feb. 2 /CNW/ -- AtheroGenics, Inc. (Nasdaq: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced an extension of its research and development collaboration with Astellas Pharma Inc. for AGI-1096, an AtheroGenics oral drug candidate being evaluated for the prevention of chronic organ transplant rejection.
